[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricle-remodeling\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricle-remodeling":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,81,118,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100578632","relive-randomized-evaluation-of-less-invasive-ventricular-enhancement-trial-100578632",false,"NCT06813820","RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial","RELIVE","Inclusion Criteria:\n\n1. 18 years old or older\n2. LV Aneurysm or Scar Presence: Defined by presence of a contiguous acontractile (akinetic and\u002For dyskinetic) non-calcified scar\n3. LV Aneurysm\u002FScar Location: Defined as a scar involving anterior, apical or anterolateral ± septal regions of the left ventricle as evidenced by cardiac imaging (Viability of myocardium in regions remote from area of intended scar exclusion as evidenced by cardiac imaging)\n4. Left Ventricular Ejection Fraction \\\u003C 40%\n5. Left ventricular end-systolic volume index ≥60 mL\u002Fm2\n6. Suffering from heart failure symptoms as defined by NYHA Classification \\> 2 not responsive to medical therapy\n7. Patient completed 6 Minute Walk Test and KCCQ Quality of Life Questionnaire (can be performed at baseline visit)\n8. Patient is on adequate Guideline Directed Medical Therapy (GDMT)\n9. Subject or a legally authorized representative must provide written informed consent\n10. Agree to required follow-up visits\n11. Female subject of childbearing potential does not plan pregnancy for at least one year following the index procedure. For a female of childbearing potential, a pregnancy test must be performed with negative results known within seven days prior to index procedure\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if ANY of the following conditions is present:\n\n1. Cardiac Resynchronization Therapy (CRT) or ICD pacing lead placement ≤ 90 days prior to enrollment\n2. Valvular heart disease, which in the opinion of the investigator, will require intervention (transcatheter or surgical)\n3. Mitral Regurgitation greater than moderate (\\>2+)\n4. Need for coronary revascularization, in the opinion of the investigator\n5. Peak Systolic Pulmonary Arterial Pressure \\> 70 mm Hg via echo or right heart catheterization\n6. Myocardial Infarction within 90 days prior to enrollment\n7. Within the last six months, a prior CVA or TIA, or intracranial hemorrhage\n8. Co-morbid disease process with life expectancy of less than one year or active malignancy not in remission\n9. Severe pulmonary disease that would preclude general anesthesia\n10. Any solid organ transplant or is on waiting list for any solid organ transplant other than cardiac\n11. Chronic renal failure with a GFR\\\u003C30ml\u002Fmin\n12. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint","ALL","18 Years",{"count":19,"type":20},135,"ESTIMATED","INTERVENTIONAL",[23],"NA","A prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with approximately 128 evaluable patients and assuming 5% loss to follow-up. A primary safety endpoint will be evaluated at 30 days. Primary efficacy endpoint will be at 1 year. Interim efficacy endpoints will be evaluated at 6 months.",[26,27,28],"Left Ventricle Remodeling","Left Ventricle Dilated","CHF",[30],"Left Ventricle Reverse remodeling","RECRUITING","2026-02-19",{"date":34,"type":35},"2026-02-20","ACTUAL",{"date":37,"type":35},"2025-09-29",{"date":39,"type":20},"2032-08",{"name":41,"class":42},"BioVentrix","INDUSTRY",6,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100498344","conventional-biventricular-versus-left-bundle-branch-pacing-on-outcomes-in-heart-failure-patients-100498344","NCT05769036","Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients","Randomized Study of Integrated Evaluation of Conventional Biventricular and Left Bundle Branch Pacing Therapy Effect on Left Ventricular Remodeling and Clinical Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction","RECOVER-HF","Inclusion criteria:\n\n1. The patient is willing and able to comply with the protocol and has provided written informed consent;\n2. Male or female patients aged 18 to 80 years;\n3. Patients with ischemic or non-ischemic cardiomyopathy;\n4. Symptomatic HF for at least 3 months prior to enrollment in the study;\n5. New York Heart Association (NYHA) functional class HF ≥ II;\n6. Patients with HF in sinus rhythm (SR) with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with LBBB morphology;\n7. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration 130-149 ms with LBBB morphology;\n8. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with non-LBBB morphology;\n9. Patients with symptomatic persistent or permanent atrial fibrillation, HF with LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) and an uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration);\n10. Patients with HF, LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) and indications for continuous ventricular pacing due to bradycardia;\n11. Patients who have received a conventional pacemaker or an implanted cardioverter-defibrillator and who subsequently develop symptomatic HF with LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) despite optimal medical therapy, and who have a significant proportion of right ventricle pacing;\n12. Optimal HF medical therapy.\n\nExclusion criteria:\n\n1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment;\n2. Acute myocardial infarction within 3 months prior to enrollment;\n3. Acute coronary syndrome;\n4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting);\n5. Patients listed for heart transplant;\n6. Patients with implanted cardiac assist device;\n7. Acute myocarditis;\n8. Infiltrative myocardial disease;\n9. Hypertrophic cardiomyopathy;\n10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves;\n11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age;\n12. Mental or physical inability to participate in the study;\n13. Patients unable or unwilling to cooperate within the study protocol;\n14. Patients with rheumatic heart disease;\n15. Mechanic tricuspid valve patients;\n16. Patients with any serious medical condition that could interfere with this study;\n17. Enrollment in another investigational drug or device study;\n18. Patients not available for follow-up;\n19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml\u002Fmin\u002F1.73 m2);\n20. Life expectancy ≤ 12 months;\n21. Participation in another telemonitoring concept.","80 Years",{"count":54,"type":20},60,[23],"Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with increased mortality, more frequent hospitalization and decreased quality of life. An initial approach to the treatment of HF patients with reduced left ventricular (LV) systolic function and left bundle branch block (LBBB) was implantation of cardioresynchronization device using biventricular pacing. This has resulted in long-term clinical benefits such as improved quality of life, increased functional capacity, reduced HF hospitalizations and overall mortality. However, conventional cardiac resynchronization therapy (CRT) is effective in only 70% of patients. And the remaining 30% of patients are non-responders to conventional CRT. Subsequently, His bundle pacing (HBP) has been developed to achieve the same results. According to other studies HBP has showed greater improvement in hemodynamic parameters than with conventional biventricular CRT. But, nevertheless, there are significant clinical troubles with HBP. In this regard, in 2017, the left bundle branch pacing (LBBP) was developed, which demonstrated clinical advantages compared to biventricular CRT. This method has become an alternative to HBP due to the stimulation of LBB outside the blocking site, a stable pacing threshold and a narrow QRS duration. A series of case reports and observational studies have demonstrated the efficacy and safety of LBBP in patients with CRT indications. However, it is not enough data about CRT with LBBP effectiveness in LV remodeling, reducing mortality and complications. According to our hypothesis, CRT with LBBP compared with conventional biventricular CRT will significantly improve the clinical outcomes and reverse LV remodeling in patients with chronic HF with reduced LV ejection fraction and reduce the number of non-responders to conventional CRT.",[58,59,60,61,62,63,26],"Heart Failure","Left Bundle-Branch Block","Ischemic Cardiomyopathy","Non-ischemic Dilated Cardiomyopathy","Left Ventricular Dysfunction","Left Ventricular Dyssynchrony",[65,66,67,68,69],"Cardiac Resynchronization Therapy","Biventricular Pacing","Left Bundle Branch Pacing","Speckle Tracking Echocardiography","Biomarker of Fibrosis and Remodeling","2025-09-03",{"date":72,"type":35},"2025-09-10",{"date":74,"type":35},"2023-10-01",{"date":76,"type":20},"2028-09-01",{"name":78,"class":79},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100604931","the-effect-of-cardiac-rehabilitation-on-left-ventricular-remodeling-in-patients-undergoing-primary-percutaneous-coronary-intervention-for-acute-myocardial-infarction-100604931","NCT07155928","The Effect of Cardiac Rehabilitation on Left Ventricular Remodeling in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction","Inclusion Criteria:\n\n1. Underwent successful primary PCI within 24 hours of symptom onset.\n2. Hemodynamically stable and able to participate in rehabilitation.\n\nExclusion Criteria:\n\n1. Stage IV Heart failure, LVEF \\\u003C 30%\n2. Life-threatening arrhythmias\n3. Unstable Angina\n4. Severe Valvular Diseases\n5. Uncontrolled Hypertension\n6. CKD Stages IV and V\n7. Hypothyroidism\n8. Cardiomyopathy\n9. Inability to ambulate or consent",{"count":88,"type":20},100,[23],"Cardiac rehabilitation has proven to improve the functional capacity of patients who had acute myocardial infarction. However, its effect on Left ventricular remodeling following an MI event treated with Primary PCI is not yet fully understood. So, for this randomized controlled trial our objectives are as follows:\n\n* Primary: To assess the effect of a structured CR program on LV remodeling parameters (LVEF, LVESV, LVEDV, LVESD, LVEDD + SWMA) in STEMI patients treated with primary PCI.\n* Secondary: To evaluate changes in exercise capacity, heart rate recovery and clinical outcomes such as major adverse cardiovascular events and the effect of CR on the patients' Quality of Life.\n\nThese results will be compared to the same parameters in a control group that will not undergo cardiac rehabilitation to properly assess the effect of cardiac rehab.\n\nParticipants in the intervention group will be asked to undergo a supervised CR program based on published guidelines (FITT principle). The core will be a moderate-intensity aerobic exercise regimen (e.g. treadmill or cycle ergometer) 2-3 times per week for 12 weeks. Each session will last \\~20-60 minutes of exercise followed by cool-down, with intensity gradually increased to High intensity interval training (HIIT) in low-moderate risk individuals, as it has shown better improvement in cardiovascular health while being safe in MI patients. Resistance exercises (e.g. light weights or band exercises) will also be included twice weekly. Exercise dose (frequency, intensity, time) will be tracked. Physical therapists will supervise all sessions in an outpatient CR facility or affiliated gym. Patients' vitals and ECG will be monitored during initial sessions for safety.",[92,93,94,95,26],"Acute Myocardial Infarction (AMI)","PCI Patients","Percutaneous Coronary Intervention (PCI)","Primary Percutaneous Coronary Intervention",[97,98,95,99,100,101,102,103,104,105,106,107],"Cardiac Rehabilitation","Acute Myocardial Infarction","Left Ventricular Remodeling","Ejection fraction","End-systolic volume","End-systolic diameter","End-diastolic volume","End-diastolic diameter","Functional capacity","Aerobic exercise","Resistance Training","NOT_YET_RECRUITING","2025-08-26",{"date":111,"type":35},"2025-09-04",{"date":113,"type":20},"2025-11",{"date":115,"type":20},"2027-12",{"name":117,"class":79},"Assiut University",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":80},"100600620","phase-4-effect-of-losartan-on-the-neurohumoral-axis-and-ventricular-remodeling-of-patients-with-severe-aortic-regurgitation-undergoing-valve-surgery-100600620","NCT07099859","Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery.","Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery","ARBNP","Inclusion criteria:\n\n* Age ≥ 18 years;\n* Postoperative period of aortic valve replacement surgery due to severe aortic regurgitation of any etiology;\n* Signed Informed Consent Form.\n\nExclusion Criteria:\n\nTo avoid potential bias in data interpretation, the following patients will be excluded:\n\n* Those who underwent cardiac surgery in the context of cardiogenic shock or infective endocarditis;\n* Patients with ischemic cardiomyopathy;\n* Patients with other significant concomitant valvular diseases.\n\nPatients with conditions where losartan use may be harmful will also be excluded, including:\n\n* Chronic kidney disease with an estimated glomerular filtration rate (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²);\n* Systolic blood pressure (SBP) \\\u003C 90 mmHg at the time of randomization;\n* Elevated serum potassium (K \\> 5.5 mEq\u002FL) at the time of randomization;\n* Pregnancy;\n* Known intolerance or allergy to losartan.","85 Years",{"count":54,"type":20},[129],"PHASE4","Why Is This Study Important? The heart has valves that help control blood flow. Aortic regurgitation (AR) is a condition where one of these valves (the aortic valve) doesn't close properly, causing blood to leak back into the heart. Over time, this makes the heart work harder and grow larger (remodeling) to keep up. Many patients with severe AR need valve replacement surgery to fix this problem.\n\nAfter surgery, the heart doesn't have to work as hard, and over time, it can shrink back to a healthier size (reverse remodeling). However, doctors don't know if medications can help speed up or improve this healing process. This study aims to find out if a common blood pressure medication, losartan, can help the heart recover better after surgery.\n\nWhat Do the Investigators Already Know? Doctors often prescribe medications like ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and spironolactone to people with heart failure because these drugs help the heart function better and prevent worsening disease. However, these medications haven't been studied in people with valve disease because most major research studies excluded patients with valve problems.\n\nEven though there is not strong evidence, many doctors prescribe these medications after valve surgery, assuming they might be helpful. But is that really the case? That's the question this study hopes to answer.\n\nWhat Is This Study About?\n\nThis study will test whether losartan, a medication often used for high blood pressure, can help hearts recover better after aortic valve replacement surgery. The researchers will compare two groups of patients:\n\n* One group will take losartan (50 mg per day) after surgery.\n* The other group will take a placebo (a pill with no active medication).\n\nBy comparing these two groups, the study will determine whether losartan helps the heart shrink back to a normal size faster and function better after surgery.\n\nHow Will the Study Work? Who? 60 patients with severe AR who are having aortic valve replacement surgery.\n\nHow? Patients will be randomly placed into one of the two groups (losartan or placebo).\n\nFor how long? Patients will be followed for one year after surgery. What Will Be Measured?\n\nDoctors will check patients four times: before surgery, and 1 month, 3 months, and 12 months after surgery. At each visit, the investigators will measure:\n\n* NT-proBNP levels: A blood test that tells us how much strain the heart is under. Lower levels mean the heart is recovering well.\n* Echocardiogram: An ultrasound of the heart to check its size and function.\n* 6-minute walk test: To see if patients feel stronger and can exercise better.\n* Quality of life survey: To understand how patients feel physically and emotionally.\n* Kidney function and electrolyte levels: To check for medication side effects.\n\nWhy Is This Study Exciting? This is the first study to test whether a medication can help the heart heal better after valve surgery. If losartan proves beneficial, it could change how doctors treat patients after surgery and lead to better recovery, stronger hearts, and healthier lives.\n\nMany people with aortic regurgitation have to wait until their symptoms get worse before patients can have surgery. If this study finds that medication can speed up healing, it could help doctors treat valve disease more effectively and improve long-term outcomes for patients.\n\nWhat Happens Next? If losartan is found to be helpful, this study could lead to larger research trials and, eventually, new treatment guidelines for people who have had aortic valve surgery. If it doesn't help, doctors will know not to prescribe it unnecessarily, preventing unnecessary side effects and costs for patients. Either way, the results will help improve care for people with heart valve disease.\n\nBy participating in this study, patients are helping researchers discover new ways to improve heart health and recovery after surgery.",[132,26,133,134,135],"Heart Valve Diseases","Aortic Regurgitation Disease","Heart Failure Congestive","Natriuretic Peptide, Brain",[137,138,139,140,141,142,143,144,145],"aortic regurgitation","valve disease","heart surgery","heart failure","losartan","Brain natriuretic peptide - BNP","biomarkers","renin-angiotensin-aldosterone system","neurohumoral axis","2025-07-29",{"date":148,"type":35},"2025-08-01",{"date":150,"type":35},"2025-07-01",{"date":152,"type":20},"2029-07-01",{"name":154,"class":79},"Vitor Emer Egypto Rosa",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":178,"locationsCount":80},"100497721","left-bundle-branch-pacing-on-outcomes-and-ventricular-remodeling-in-biventricular-crt-nonresponders-100497721","NCT05760924","Left Bundle Branch Pacing on Outcomes and Ventricular Remodeling in Biventricular CRT Nonresponders","Randomized Trial of Left Bundle Branch Pacing Effect on Clinical Outcomes and Left Ventricular Remodeling in Patients With Nonresponse to Biventricular Cardiac Resynchronization Therapy","RESCUE","Inclusion criteria:\n\n1. The patient is willing and able to comply with the protocol and has provided written informed consent;\n2. Male or female patients aged 18 to 80 years;\n3. Patients with ischemic or non-ischemic cardiomyopathy;\n4. Symptomatic HF for at least 3 months prior to enrollment in the study;\n5. New York Heart Association (NYHA) functional class HF ≥ II;\n6. Patients who are non-responders to biventricular CRT with HF, reduced LVEF and CRT-D replacement or one of the CRT-D leads replacement indications (without LVEF increase ≥ 5% and\u002For without a left ventricle end-systolic volume decrease ≥ 15% after CRT-D implantation at least 1 year old);\n7. Optimal HF medical therapy.\n\nExclusion criteria:\n\n1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment;\n2. Acute myocardial infarction within 3 months prior to enrollment;\n3. Acute coronary syndrome;\n4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting);\n5. Patients listed for heart transplant;\n6. Patients with implanted cardiac assist device;\n7. Acute myocarditis;\n8. Infiltrative myocardial disease;\n9. Hypertrophic cardiomyopathy;\n10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves;\n11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age;\n12. Mental or physical inability to participate in the study;\n13. Patients unable or unwilling to cooperate within the study protocol;\n14. Patients with rheumatic heart disease;\n15. Mechanic tricuspid valve patients;\n16. Patients with any serious medical condition that could interfere with this study;\n17. Enrollment in another investigational drug or device study;\n18. Patients not available for follow-up;\n19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml\u002Fmin\u002F1.73 m2);\n20. Life expectancy ≤ 12 months;\n21. Participation in another telemonitoring concept.",{"count":164,"type":20},30,[23],"Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with the increased mortality, more frequent hospitalization and decreased quality of life. An initial approach to the treatment of HF patients with reduced left ventricular (LV) systolic function and left bundle branch block (LBBB) was implantation of device for cardiac resynchronization therapy using biventricular pacing. This has resulted in long-term clinical benefits such as improved quality of life, increased functional capacity, reduced HF hospitalizations and overall mortality. However, conventional cardiac resynchronization therapy (CRT) is effective in only 70% of patients. And the remaining 30% of patients are non-responders to conventional CRT. Cardiac conduction system pacing is currently a promising technique for these patients. Particularly, His bundle pacing (HBP) has been developed to achieve the same results. According to other studies HBP has shown greater improvement in hemodynamic parameters comparing with conventional biventricular CRT. But, nevertheless, there are significant clinical troubles with HBP, especially high pacing threshold. In this regard, in 2017, the left bundle branch pacing (LBBP) was developed, which demonstrated clinical advantages compared to conventional biventricular CRT. Also, since 2019, left bundle branch pacing-optimized CRT (LBBPO CRT) has been used in clinical practice. These methods have become an alternative to HBP due to the stimulation of LBB outside the blocking site, a stable pacing threshold and a narrow QRS complex duration on electrocardiogram. A series of case reports and observational studies have demonstrated the efficacy and safety of LBBP and LBBPO CRT in patients with CRT indications. However, it is not enough data about impact of CRT with LBBP and combined CRT with LBBP and LV pacing on myocardial remodeling, reducing mortality and complications. According to our hypothesis, CRT with LBBP and combined CRT with LBBP and LV pacing compared with conventional biventricular pacing will significantly improve the clinical outcomes and reverse myocardial remodeling in patients who are non-responders to biventricular CRT with HF, reduced LV ejection fraction and with indications to CRT devices with defibrillator function (CRT-D) or one of the CRT-D leads replacement.",[58,59,60,61,62,26],[65,66,67,68,69,169,170,171],"Combined Left Bundle Branch and Left Ventricular Pacing","CRT Non-responder","CRT Responder","2024-11-20",{"date":174,"type":35},"2024-11-22",{"date":176,"type":35},"2024-11-01",{"date":76,"type":20},{"name":78,"class":79}]